NTC presents positive results from Phase II Mirakle study evaluating an innovative drug for bacterial conjunctivitis
December 05, 2024 | 18:00
NTC, an international R&D focused pharmaceutical company headquartered in Italy , presents positive results from Phase II MIRAKLE study.
Mobile Version